Compass Therapeutics, INC Form 4 insider transactions

General Counsel Jonathan Anderman acquired 25,000 shares of Compass Therapeutics common stock in an open market purchase.

Jonathan Anderman, General Counsel of Compass Therapeutics, Inc., acquired 25,000 shares of common stock.

Neil Lerner, Chief Accounting Officer at Compass Therapeutics, Inc., acquired 15,000 shares of common stock on April 29, 2026.

Compass Therapeutics CEO Thomas J. Schuetz disposed of 36,687 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Compass Therapeutics CEO Thomas J. Schuetz reported the sale of 46,777 shares of common stock to cover tax withholding obligations related to RSU vesting.

Compass Therapeutics General Counsel Jonathan Anderman received 150,000 restricted stock units and 720,000 stock options.

Compass Therapeutics' CFO, Barry Shin, was granted 125,000 restricted stock units and 670,000 stock options on January 2, 2026.

Compass Therapeutics, Inc. has granted its Chief Medical Officer, Cynthia Sirard, 1,000,000 stock options as an inducement for her employment.

Compass Therapeutics CEO Thomas J. Schuetz acquired 250,000 restricted stock units and 2,000,000 stock options, signaling increased equity alignment.

Compass Therapeutics, Inc. granted Chief Commercial Officer Arjun Prasad 1,000,000 stock options at $5.17 per share as an inducement for his employment.

Compass Therapeutics director Richard S. Lindahl received a grant of 90,000 stock options with an exercise price of $5.17, vesting by June 2026 or the next annual meeting.

Compass Therapeutics, Inc. Director Ellen Chiniara was granted 90,000 stock options with an exercise price of $5.17, vesting by June 2026.

Compass Therapeutics' Chief Accounting Officer, Neil Lerner, was granted 62,500 restricted stock units and 435,000 stock options as part of an equity compensation package.

Compass Therapeutics Director Mary Ann Gray was granted 90,000 stock options with an exercise price of $5.17, vesting upon the earlier of June 10, 2026, or the next annual meeting.

Compass Therapeutics Director James P. Boylan was granted 90,000 stock options with an exercise price of $5.17, vesting by mid-2026.

Compass Therapeutics Director Carl L. Gordon was granted 90,000 stock options with an exercise price of $5.17, vesting by June 2026 or the next annual meeting.

Compass Therapeutics Director Philip Ferneau was granted 90,000 stock options with an exercise price of $5.17, vesting by June 2026 or the next annual meeting.

Compass Therapeutics CEO Thomas J. Schuetz disposed of 44,025 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Compass Therapeutics, Inc. CEO and Director Thomas J. Schuetz has acquired 10,000 shares of the company's common stock at a weighted average price of $2.11 per share, increasing his total beneficial ownership to over 6.48 million shares.

Carl L. Gordon, a director and 10% owner of Compass Therapeutics, Inc., reports changes in beneficial ownership of common stock due to transactions on April 9, 2025.

OrbiMed Advisors LLC reports the disposition of 3,571,428 shares of Compass Therapeutics, Inc. at a price of $1.59 per share.

Jonathan Anderman, General Counsel & Corporate Secretary of Compass Therapeutics, purchased 20,000 shares of common stock at $1.54 per share on April 7, 2025.

Neil Lerner, Chief Accounting Officer of Compass Therapeutics, recently acquired 20,000 shares of common stock at an average price of $1.42 per share, increasing his direct holdings in the company.

Barry Shin, CFO of Compass Therapeutics, was granted stock options to purchase 250,000 shares of common stock.

Compass Therapeutics CEO Thomas J. Schuetz was granted 1,500,000 stock options on February 11, 2025, according to a recent SEC filing.

Director Richard S. Lindahl of Compass Therapeutics, Inc. acquired 40,000 stock options on February 11, 2025, according to a Form 4 filing.

Neil Lerner, SVP and CAO of Compass Therapeutics, was granted stock options for 200,000 shares on February 11, 2025, vesting monthly over four years.

Mary Ann Gray, a director at Compass Therapeutics, acquired stock options for 40,000 shares at an exercise price of $3.65 on February 11, 2025.

Director Philip Ferneau acquired 40,000 stock options in Compass Therapeutics, Inc. on February 11, 2025.

Director Ellen Chiniara acquired 40,000 stock options in Compass Therapeutics (CMPX) on February 11, 2025, according to a Form 4 filing.